TRANSITION BIO
Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.
TRANSITION BIO
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.transitionbio.com
Total Employee:
11+
Status:
Active
Total Funding:
50 M USD
Technology used in webpage:
Euro LetsEncrypt Invalid Certificate Dates Unified Layer
Similar Organizations
Alpheus Medical
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.
Aquafortus
Aquafortus is a non-thermal recovery and crystallization technology platform.
ArrePath
ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
Chemify
Digitising Chemistry and Chemical Discovery
Elephas
A live tumor imaging diagnostics company
General Fluidics
General Fluidics is a vitro diagnostic company.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Orange Health
Orange Health is a HealthTech startup that allows doctors to deliver diagnostic lab services to patients remotely.
Prenuvo
Prenuvo offers whole body MRI screening - we provide deep insights for earlier detection.
Current Advisors List
Board_member
Board_member
2022-06-02
Board_member
Current Employees Featured
Martin Kulander Chief Operating Officer @ Transition Bio
Chief Operating Officer
2021-06-01
Gregory Miller Chief Executive Officer @ Transition Bio
Chief Executive Officer
2021-09-01
Peter St George-Hyslop Scientific Co-Founder @ Transition Bio
Scientific Co-Founder
Sarah Teichmann Scientific Co-Founder @ Transition Bio
Scientific Co-Founder
Tuomas Knowles CTO @ Transition Bio
CTO
2021-10-01
David Weitz Scientific Co-Founder @ Transition Bio
Scientific Co-Founder
Founder
Investors List
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series A - Transition Bio
Northpond Ventures
Northpond Ventures investment in Series A - Transition Bio
Taiho Ventures
Taiho Ventures investment in Series A - Transition Bio
Magnetic Ventures
Magnetic Ventures investment in Series A - Transition Bio
Lifeforce Capital
Lifeforce Capital investment in Series A - Transition Bio
Lifeforce Capital
Lifeforce Capital investment in Seed Round - Transition Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-14 | Transition Bio Shifting into Second Gear with New Executive Team |
Official Site Inspections
http://www.transitionbio.com Semrush global rank: 1.15 M Semrush visits lastest month: 23.74 K
- Host name: box5455.bluehost.com
- IP address: 162.241.217.42
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
Transitionbio.com lookup results from whois.domain.com server:
- Domain created: 6th-Apr-2020
- Domain updated: 22nd-Mar-2025
- Domain expires: 6th-Apr-2026 0 Years, 298 Days left
- Website age: 5 Years, 65 Days
- Registrar Domain ID: 2511894380_DOMAIN_COM-VRSN
- Registrar Url: http://www.domain.com
- Registrar WHOIS Server: whois.domain.com
- Registrar Abuse Contact Email: compliance@domain-inc.net
- Registrar Abuse Contact Phone: 602-226-2389
- Name server:
- NS1.DOMAIN.COM
- NS2.DOMAIN.COM
More informations about "Transition Bio"
About Us - Transition Bio
Mr. Martin is the Executive Chairman and co-founder of Transition Bio. Mr. Martin is the former Chief Executive Officer of Radius Health, an innovative endocrine therapeutics …See details»
Transition Bio, Inc. - LinkedIn
Transition Bio, Inc. Biotechnology Research Cambridge, Massachusetts 5,438 followers One-of-a-kind technologies for biomolecular condensate analysis.See details»
Our Science - Transition Bio
Our Science & Pipeline. Condensates are membraneless organelles in cells that are comprised of proteins and nucleic acids. These biomolecular assemblies are involved in many cellular processes fundamental to cellular homeostasis. …See details»
Our Team - www.transitionbio.com
David A. Weitz. Harvard University Mallinckrodt Professor of Physics & Applied Physics & Professor of Systems Biology. Experimentalist with a focus on soft matter physics, biophysics, …See details»
Our Science - www.transitionbio.com
Learn more about Transition Bio's science. Condensate Technology. We harness droplet microfluidic approaches, protein biophysics, and cellular platforms to characterize …See details»
Transition Bio, Inc. | LinkedIn
Transition Bio, Inc. | 5,046 followers on LinkedIn. One-of-a-kind technologies for biomolecular condensate analysis. | Transition Bio is developing one-of-a-kind technologies for biomolecular …See details»
Home - www.transitionbio.com
Condensomics™ Our team in Cambridge, MA and Cambridge, UK has created one-of-a-kind technologies for biomolecular condensate analysis. Through Condensomics™, our goal is to …See details»
Transition Bio Ltd. - life-sciences-europe.com
Jun 2, 2022 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry …See details»
Transition Bio - Contacts, Employees, Board Members
Organization. Transition Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. Number of …See details»
Transition Bio Company Profile 2024: Valuation, Funding
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most. Information on valuation, funding, cap tables, …See details»
Transition Bio - Craft
Transition Bio has 5 employees across 2 locations and $50 m in total funding,. See insights on Transition Bio including office locations, competitors, revenue, financials, executives, …See details»
Transition Bio, Inc. Closes Seed Financing and Launches Company
Nov 30, 2020 CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Transition Bio, Inc. (“Transition Bio” or the “Company”) was recently formed, funded, and launched with …See details»
Contact Us - Transition Bio
Bringing droplet microfluidics and machine learning together for novel drug discovery.See details»
Transition Bio, Inc., Expands Leadership Team, Names CEO, CTO, …
Oct 12, 2021 CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Transition Bio, Inc. (the Company) today named several critical additions to its leadership team, including …See details»
Transition Bio Closes $50 Million Series A Financing to Accelerate ...
Jun 2, 2022 CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Transition Bio, Inc., a microfluidics-driven drug discovery platform company using biophysical sciences and …See details»
Transition Bio, Inc. Closes Seed Financing and Launches Company
Nov 30, 2020 CAMBRIDGE, Mass. & CAMBRIDGE, England–(BUSINESS WIRE)–Transition Bio, Inc. (“Transition Bio” or the “Company”) was recently formed, funded, and launched with …See details»
Our Locations - www.transitionbio.com
Where to find Transition Bio in the U.S. and UK.See details»
News - Transition Bio
Transition Bio is a dynamic, fast-growing company. Come back for regular updates. News and Events Posters and PresentationsSee details»
Professor Peter St George-Hyslop Joins Transition Bio as Scientific …
Feb 22, 2021 CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Transition Bio, Inc. (“Transition Bio” or the “Company”) announced today that Professor Peter St George …See details»